Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT03691714Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Oct 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Cincinnati. Primary endpoint: Objective Response Rate at 8.5 months. Started Oct 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03691714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691714.